Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Anar Andani"'
Autor:
Ray Borrow, Federico Martinón-Torres, Véronique Abitbol, Anar Andani, Scott Preiss, Alessandro Muzzi, Laura Serino, Woo-Yun Sohn
Publikováno v:
Expert Review of Vaccines, Vol 22, Iss 1, Pp 738-748 (2023)
Introduction Neisseria meningitidis serogroup B (NmB) antigens are inherently diverse with variable expression among strains. Prediction of meningococcal B (MenB) vaccine effectiveness therefore requires an assay suitable for use against large panels
Externí odkaz:
https://doaj.org/article/4e1c2a33874d4f68b50c1a9a666b28e7
Autor:
Dasha Shamarina, Martina Sluga-O’Callaghan, George Kassianos, Alen Marijam, Vaidehi Dave, Eric Davenport, Anar Andani, Desmond Curran, Pavitra Dewda, Robert Steffen
Publikováno v:
Vaccines, Vol 11, Iss 11, p 1645 (2023)
Despite the occurrence of several hepatitis A (hepA) and hepatitis B (hepB) outbreaks in Europe in the last few decades, not all European countries have implemented hepA and hepB vaccinations in their national immunization programs, especially for ad
Externí odkaz:
https://doaj.org/article/9739304f4aa94cbcaa1df620f3697058
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 5, Pp 1520-1529 (2021)
The burden of chronic liver disease (CLD) in India is high, particularly among middle-aged men, with nearly 220,000 deaths due to cirrhosis in 2017. CLD increases the risk of infection, severe disease (e.g. hepatitis A virus or HAV superinfection, ac
Externí odkaz:
https://doaj.org/article/6a232a0fed5b499b89de492f70fecdc5
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 1 (2022)
In the last two decades, outbreaks due to the foodborne hepatitis A virus (HAV) have been frequently reported in India, with adolescents and adults primarily affected. In India, most food handlers are adolescents and young adults who might be exposed
Externí odkaz:
https://doaj.org/article/2566456d46c0480eaf8ad7c6af40b1a0
Autor:
Adriana Guzman-Holst, Gerardo Luna-Casas, Ana Burguete Garcia, Vicente Madrid-Marina, Maria Yolanda Cervantes-Apolinar, Anar Andani, Gloria Huerta-Garcia, Gilberto Sánchez-González
Publikováno v:
PLoS ONE, Vol 17, Iss 5, p e0268469 (2022)
BackgroundHepatitis A virus (HAV) infection is a leading cause of viral hepatitis in children, yet the HAV vaccine is not included in the national immunization program (NIP) in Mexico. This study addresses an identified evidence gap of the burden of
Externí odkaz:
https://doaj.org/article/6de19511fda64c60b2bdc97aed66ef05
Autor:
Ashish Agrawal, Shafi Kolhapure, Anar Andani, Martin O. C. Ota, Selim Badur, Naveen Karkada, Monjori Mitra
Publikováno v:
Infectious Diseases and Therapy, Vol 9, Iss 4, Pp 785-796 (2020)
Abstract Introduction Hepatitis A virus infection is more severe in adults than children. Although vaccination can protect adults, current childhood programs cover a large population more successfully. Childhood vaccination is, therefore, a solution
Externí odkaz:
https://doaj.org/article/b4111448187241bdb9099bd61a6e323e
Autor:
Anar Andani, Kassiani Mellou, Eveline Bunge, Jennifer Eeuwijk, George Kassianos, Pierre Van Damme, Robert Steffen
Publikováno v:
Open Forum Infectious Diseases. 9
Background Hepatitis A (HepA) global burden is estimated to be > 100 million new cases/year. HepA is vaccine-preventable, but outbreaks still occur in regions with low endemicity such as Europe. Guidelines for HepA vaccination in adult risk groups ar
Publikováno v:
Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record
article-version (VoR) Version of Record
The burden of chronic liver disease (CLD) in India is high, particularly among middle-aged men, with nearly 220,000 deaths due to cirrhosis in 2017. CLD increases the risk of infection, severe disease (e.g. hepatitis A virus or HAV superinfection, ac
Autor:
Fernanda Salgado, Anar Andani, Bernard Hoet, Pierre Van Damme, Eveline M Bunge, Rosa C. van Hoorn
Publikováno v:
Vaccine
Background: Hepatitis A virus (HAV) is a global health concern as outbreaks continue to occur. Since 1999, several countries have introduced universal vaccination (UV) of children against HAV according to approved two-dose schedules. Other countries
Autor:
Anar Andani, Cinzia Marano, Eveline M Bunge, Kathryn H. Jacobsen, Fernanda Salgado, Tessa M van Elten
Publikováno v:
Expert Review of Vaccines. 19:795-805
The World Health Organization recommends vaccination against hepatitis A virus (HAV) for children aged 1 year and older in areas where endemicity has shifted from high to intermediate. There are no recent comprehensive reviews of the epidemiology of